Delestrogen Shortage Update: March 2026

If you're a patient who depends on Delestrogen (Estradiol Valerate injection) for menopause treatment, hormone replacement, or gender-affirming care, you probably already know that finding it can be a challenge. This article provides the most current information on the shortage as of early 2026.

Current Status: Intermittent Shortages Continue

As of March 2026, Estradiol Valerate injection — both brand-name Delestrogen and generic versions — continues to experience intermittent supply issues across the United States. While the situation has improved compared to the most acute shortage periods of 2016-2017 and 2022-2023, patients in many areas still report difficulty finding the medication.

The American Society of Health-System Pharmacists (ASHP) has tracked Estradiol Valerate injection on its drug shortage list multiple times over the past decade. Supply availability varies significantly by region, pharmacy, and concentration (10 mg/mL, 20 mg/mL, or 40 mg/mL).

What's Causing the Ongoing Supply Issues?

The Delestrogen shortage is driven by a combination of factors that haven't fully resolved:

Limited Manufacturers

The injectable Estradiol Valerate market has very few producers. Par Pharmaceutical (now part of Endo International) manufactures the brand-name Delestrogen, while companies like Perrigo produce generic versions. With so few manufacturers, any single production disruption has an outsized impact on nationwide supply.

Increasing Demand

Demand for injectable estrogen has grown steadily, driven largely by:

• Expanded access to gender-affirming hormone therapy
• Growing awareness and acceptance of transgender healthcare
• Patient preference for injectable over oral estrogen due to better safety profile regarding blood clots
• Increased prescribing by telehealth platforms, making hormone therapy more accessible

Manufacturing Complexity

Injectable medications require sterile manufacturing environments and specialized equipment. The oil-based formulation of Estradiol Valerate (using sesame oil or castor oil) adds production complexity. Quality control requirements for injectable medications are more stringent than for oral forms, meaning production setbacks take longer to resolve.

Raw Material Sourcing

The active pharmaceutical ingredient (estradiol valerate) and the carrier oils must meet strict quality standards. Global supply chain challenges can delay raw material delivery, slowing production.

What Manufacturers Are Saying

Information from manufacturers has been limited. Par Pharmaceutical has not publicly disclosed detailed reasons for supply constraints. Some generic manufacturers have cited manufacturing delays without providing specific timelines for resolution. The FDA's drug shortage database has listed and delisted Estradiol Valerate injection multiple times.

How This Affects Patients

The ongoing shortage creates real hardship for patients who depend on Delestrogen:

• Treatment interruptions: Gaps in hormone therapy can cause menopausal symptoms to return (hot flashes, mood changes, vaginal dryness) and may have long-term health implications
• Emotional distress: For transgender patients, interruptions in feminizing hormone therapy can be deeply distressing and impact mental health
• Financial burden: Patients may need to pay more for alternative formulations, visit multiple pharmacies, or use compounding pharmacies that aren't covered by insurance
• Time burden: Hours spent calling pharmacies and coordinating with doctors to find alternatives

What You Can Do Right Now

Here are actionable steps to manage through the shortage:

1. Refill Early

Don't wait until you're on your last dose. Most insurance plans allow you to refill when you've used 75-80% of your current supply. Set a reminder on your phone to call in refills early.

2. Use MedFinder

MedFinder helps patients locate pharmacies that have hard-to-find medications in stock. Search for Delestrogen or Estradiol Valerate injection and enter your zip code to find nearby availability.

3. Accept Any Available Strength

Delestrogen comes in 10 mg/mL, 20 mg/mL, and 40 mg/mL. If your usual concentration isn't available, your doctor can adjust your injection volume to use a different concentration. Ask your pharmacist to check all three strengths.

4. Ask About Generic

Generic Estradiol Valerate injection is therapeutically equivalent to brand Delestrogen and may be more readily available. It's also typically less expensive.

5. Explore Alternatives

If you can't find any injectable Estradiol Valerate, talk to your doctor about alternatives like Estradiol Cypionate, estradiol patches, oral estradiol, or compounded injections.

6. Contact Your Prescriber

Your doctor's office may have leads on pharmacy availability or be able to connect you with specialty pharmacies. Some clinics that specialize in hormone therapy maintain their own stock or have preferred pharmacy partners.

What's Being Done?

Efforts to address the shortage include:

• FDA monitoring: The FDA tracks the shortage and works with manufacturers to increase production
• Generic competition: Additional generic manufacturers may enter the market, though the process of FDA approval and manufacturing setup takes time
• Compounding access: Compounding pharmacies continue to fill the gap, though questions about insurance coverage and quality standardization remain
• Advocacy: Patient advocacy organizations and healthcare providers continue to push for policy changes to prevent future shortages of essential medications

Looking Ahead

While the shortage situation is expected to gradually improve as manufacturers ramp up production, patients should plan for continued intermittent availability through 2026. Building a relationship with your pharmacist, having a backup plan with your doctor, and using tools like MedFinder are your best strategies.

For more information, read about why Delestrogen is so hard to find, learn how to find it in stock near you, or explore ways to save money on Delestrogen.